Treace Medical Concepts (NASDAQ:TMCI – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.05), Briefing.com reports. The company had revenue of $44.46 million during the quarter, compared to analyst estimates of $43.00 million. Treace Medical Concepts had a negative net margin of 27.93% and a negative return on equity of 39.66%. Treace Medical Concepts’s revenue for the quarter was up 6.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.20) EPS. Treace Medical Concepts updated its FY 2024 guidance to EPS.
Treace Medical Concepts Stock Performance
NASDAQ TMCI traded down $0.04 during trading on Wednesday, reaching $6.62. The company’s stock had a trading volume of 2,822,535 shares, compared to its average volume of 919,963. Treace Medical Concepts has a twelve month low of $3.92 and a twelve month high of $20.77. The firm has a market cap of $410.49 million, a price-to-earnings ratio of -7.35 and a beta of 0.23. The business’s fifty day moving average price is $6.71 and its 200-day moving average price is $9.89. The company has a debt-to-equity ratio of 0.42, a quick ratio of 3.22 and a current ratio of 3.98.
Insider Buying and Selling
In related news, CEO John T. Treace acquired 45,000 shares of the firm’s stock in a transaction on Tuesday, June 11th. The stock was bought at an average cost of $5.88 per share, with a total value of $264,600.00. Following the transaction, the chief executive officer now owns 6,388,095 shares of the company’s stock, valued at $37,561,998.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Treace Medical Concepts news, Director Richard W. Mott acquired 36,802 shares of the stock in a transaction on Monday, May 13th. The shares were bought at an average price of $4.38 per share, with a total value of $161,192.76. Following the acquisition, the director now owns 1,027,753 shares of the company’s stock, valued at $4,501,558.14. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John T. Treace bought 45,000 shares of the company’s stock in a transaction on Tuesday, June 11th. The shares were acquired at an average price of $5.88 per share, for a total transaction of $264,600.00. Following the transaction, the chief executive officer now directly owns 6,388,095 shares in the company, valued at approximately $37,561,998.60. The disclosure for this purchase can be found here. Insiders have purchased a total of 593,902 shares of company stock valued at $2,930,422 over the last quarter. 24.43% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
Get Our Latest Research Report on Treace Medical Concepts
About Treace Medical Concepts
Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.
Featured Stories
- Five stocks we like better than Treace Medical Concepts
- How to Effectively Use the MarketBeat Ratings Screener
- What Are Bonds? A High-Level Overview
- How to Find Undervalued Stocks
- Super Micro Stock Drops Sharply After Earnings on Margin Concerns
- How to Capture the Benefits of Dividend Increases
- Lyft’s First-Ever Profit, but the Outlook Is a Speed Bump
Receive News & Ratings for Treace Medical Concepts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Treace Medical Concepts and related companies with MarketBeat.com's FREE daily email newsletter.